Roche in HIV
Pharmaceutical Products
Diagnostics Products
Commitment to Access
  Protease Inhibitor Pricing Policy for LDC and SSA
  Protease Inhibitor Pricing Policy for LI and LMI Countries
  Roche and Malaria
  CARE - Roche HIV/AIDS Partnership in Africa
Site Resources
Understanding HIV
  Useful Links
  Site Map

Protease inhibitors Pricing Policy for LDC and SSA

Since 2002, Roche has offered its HIV protease inhibitors, Invirase and Viracept, at no profit prices for direct supplies from the headquarters inBasel,Switzerland, to all Least Developed Countries, as defined by United Nations, and sub-SaharanAfrica. 

The no profit prices are reviewed on an annual basis to ensure the prices remain truly no profit to Roche. They are the lowest prices at which Invirase and Viracept can be provided by Roche in a sustainable manner.

Prices have been included below for your information and are applicable to all orders from eligible countries. These prices apply to all presentations of Roche’s protease inhibitors.

Summary  of no profit prices available for direct purchase from Roche Basel.
(Prices effective as of 1st August 2006 )

Invirase® 200 mg
Price per pack
(270 x 200mg capsules) / CHF

Invirase® 500 mg
Price per pack
(120 x 500mg tablets) / CHF

Price per pack
(270 x 250mg tablets) / CHF

Paediatric powder
Price per 144g pack / CHF





These no profit prices do not reflect research or development costs, marketing costs, distribution costs or company overheads. The terms and conditions under which Roche’s no profit prices are applicable remain unchanged. 

Roche will continue to review its no profit prices on an annual basis for as long as the company supplies these medicines.

Least Developed Countries (LDC):
List is correct as of October 2008
Afghanistan, Angola, Bangladesh, Benin, Bhutan, Burkina Faso, Burundi, Cambodia, Cape Verde, Central African Republic, Chad, Comoros, Democratic Republic of the Congo, Djibouti, Equatorial Guinea, Eritrea, Ethiopia, Gambia, Guinea, Guinea-Bissau, Haiti, Kiribati, Lao People’s Democratic Republic, Lesotho, Liberia, Madagasgar, Malawi, Maldives, Mali, Mauritania, Mozambique, Myanmar, Nepal, Niger, Rwanda, Samoa, Sao Tome and Principe, Senegal, Sierra Leone, Solomon Islands, Somalia, Sudan, United Republic of Tanzania, Timor-Leste, Togo, Tuvalu, Uganda, Vanuatu, Yemen, Zambia.

Sub-Saharan African (SSA) Countries (Not included in UN list of LDCs):
Botswana, Cameroon, Congo Republic, Côte D’Ivoire, Gabon, Ghana, Kenya, Mauritius, Namibia, Nigeria, Seychelles, South Africa, Swaziland, Zimbabwe.

Roche’s commitment to increasing access to HIV healthcare globally
Roche is committed to increasing access to HIV healthcare globally through the development of healthcare solutions that are sustainable and have a long-term impact, particularly on the lives of those in the Least Developed Countries and sub-Saharan Africa.  Roche is a founding member of the Accelerating Access Initiative, which aims to provide sustainable access to HIV care and treatment in resource limited countries.   

Terms and Conditions associated with the Pricing Policy for SSA, LDCs and Low Income and Lower Middle Income countries

  • Minimum order and delivery amount per shipment is CHF 10’000.
  • Under circumstances where Roche is requested to provide delivery, distribution costs as well as import taxes and duties must be added.  Local retail prices are therefore higher than these ex-RocheBaselprices.
  • These prices are provided subject to the conditions that the drug will not be diverted or re-exported to other countries not qualifying for the specified price
  • FCA Basel (Incoterms 2000)
  • CAD (Cash Against Documents/Cash on Delivery) 30 days at sight
  • Swiss Franc invoicing (CHF)
  • All purchasers placing orders for reduced priced HIV medicines from Roche Basel will be required to provide the final delivery destination and recipient name in order to enable tracking and monitoring of product supply

In order to achieve the lowest no profit price level for Viracept, Roche’s licensing partners Agouron/Pfizer and Japan Tobacco, who hold the patent rights of Viracept, have agreed to waive all royalties on the sales of the product in qualifying countries.

Roche Company contact for ordering and logistics issues only:

Sandra Torriani
Demand Manager
F.Hoffmann-La Roche Ltd., Basel
Building 237/2.17
CH 4303 Switzerland
Phone: +41 61 688 9390
Fax: +41 61 687 1815
Email: [email protected]

For other information concerning eligibility and pricing please contact:

René Imhof
Head of Operational Pricing (PBSO)
Phone: +41 61 687 3930
Fax: +41 61 688 1525
Email: [email protected]

Print Print
All information contained in this website is generated and maintained by F. Hoffmann-La Roche, Ltd, Basel, Switzerland.
This site is intended for use by healthcare professionals only. This site is not intended for residents of the United States of America.
Copyright 2006 F. Hoffmann La Roche Ltd. - Disclaimer.
Contact webmaster